Development of a novel 3-month drug releasing risperidone microspheres
Objective: The purpose of this study was to develop an ideal microsphere formulation of risperidone that would prolong the drug release for 3 months in vivo and avoid the need for co-administration of oral tablets. Materials and Methods Polycaprolactones (PCL) were used as polymers to prepare micros...
Saved in:
Main Authors: | Bhanusree Yerragunta (Author), Satheesh Jogala (Author), Krishna Mohan Chinnala (Author), Jithan Aukunuru (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies
by: Aerrolla Navitha, et al.
Published: (2014) -
Development of subcutaneous sustained release nanoparticles encapsulating low molecular weight heparin
by: Satheesh Jogala, et al.
Published: (2015) -
Risperidone Controlled Release Microspheres Based on Poly(Lactic Acid)-Poly(Propylene Adipate) Novel Polymer Blends Appropriate for Long Acting Injectable Formulations
by: Stavroula Nanaki, et al.
Published: (2018) -
Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide
by: Yuxuan Ge, et al.
Published: (2021) -
Quantification of Microsphere Drug Release by Fluorescence Imaging with the FRET System
by: Yuying Chen, et al.
Published: (2024)